Trial Profile
A Phase I and Randomized Phase II Study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in Relapsed, Refractory Diffuse Large-B Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 Sep 2023
Price :
$35
*
At a glance
- Drugs Mogamulizumab (Primary) ; Pembrolizumab (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 29 Aug 2023 Status changed from active, no longer recruiting to completed.
- 14 Feb 2023 Planned End Date changed from 1 Jul 2023 to 13 Feb 2024.
- 15 Sep 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.